Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation

Vemurafenib has been developed to target common BRAF mutation V600E. It also exerts activity towards some but not all rare BRAF substitutions. Proper cataloguing of drug-sensitive and -insensitive rare mutations remains a challenge, due to low occurrence of these events and inability of commercial P...

Descripción completa

Detalles Bibliográficos
Autores principales: Moiseyenko, Fedor V., Egorenkov, Vitaliy V., Kramchaninov, Mikhail M., Artemieva, Elizaveta V., Aleksakhina, Svetlana N., Holmatov, Maxim M., Moiseyenko, Vladimir M., Imyanitov, Evgeny N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547278/
https://www.ncbi.nlm.nih.gov/pubmed/31182949
http://dx.doi.org/10.1159/000500481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547278/
https://www.ncbi.nlm.nih.gov/pubmed/31182949
http://dx.doi.org/10.1159/000500481

Ejemplares similares